New hypertension drug combo enters first human tests
NCT ID NCT07312799
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will test two experimental drugs, AD-2321 and AD-2322, in 41 healthy adults to see how they interact in the body. The study focuses on safety and how the drugs are processed, not on treating high blood pressure. Results will guide future studies in patients with hypertension.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AD-2321 and AD-2322 oral tablets
What this could lead to
If successful, this study could help determine safe dosing for a future hypertension treatment.
What could go wrong
This is a very early Phase 1 trial in healthy volunteers, not patients. It only measures drug levels and safety, not whether the drugs actually lower blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
H+ Yangji Hospital
Seoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••